Release Time:2026-05-20 11:23:54Source:Eyebright
In recent weeks, the Company participated in multiple leading international medical exhibitions, strengthening market expansion through innovative products and proven technical capabilities.
Invited to Attend Swiss Biotech Week to Enhance Eyebright Medical Influence in the European Market
On May 4, Eyebright Medical was officially invited to participate in Swiss Biotech Week for the second consecutive year by the Swiss Business Hub China.

As an important step toward building a resilient global operating system, Eyebright Medical has established a wholly owned subsidiary in Switzerland. The initiative aims to support European business and marketing functions in reflection of its internationalization strategy.
Endorsed by the Hong Kong Science Park and Showcasing Leading Strength in Ophthalmology
On May 11, Eyebright Medical exhibited at the Hong Kong International Medical & Healthcare Expo and secured a booth in the Hong Kong Science & Technology Parks pavilion.
As one of only two ophthalmology-focused medical enterprises recommended by the Hong Kong Science & Technology Parks for this year, the selection reflects both the Company’s recognized R&D capabilities and product quality, as well as industry confidence in Eyebright Medical’s global development potential. The Company also held in-depth discussions with relevant channel partners and medical institutions to support expansion in the Greater Bay Area and beyond.
Expanding in Central Asia at Kazakhstan VisionCare Optometry Exhibition
On May 20, Eyebright Medical participated in the VisionCare International Optometry Exhibition in Almaty, Kazakhstan from May 20–22, 2026.

The exhibition covers a wide range of cutting-edge fields, including ophthalmology, medical devices, pharmaceuticals, and diagnostic equipment. It is one of the largest and most professional healthcare exhibitions in the Central Asia region. Taking this opportunity, Eyebright Medical will actively expand into the Central Asian market, promote the implementation of key products in the ophthalmology sector, and accelerate the company’s strategic layout and market penetration across countries along the “Belt and Road” Initiative.